Health Condition 1: U071- COVID 19 virus identified Health Condition 2: J988- Other specified respiratory disorders
Conditions
Interventions
Intervention1: 101-PGC-005: 101-PGC-005 20 mg inj. once daily for 3 days + SOC
Control Intervention1: Dexamethasone: Dexamethasone 6mg inj once daily for max. 10 days + SOC
Sponsors
LAXAI LIFE SCIENCES PVT. LTD.,
One O One Therapeutics
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients willing and able to provide voluntary written informed consent and to follow the protocol specific requirements. 2. Male or female patients of age 18 to 65 years (both inclusive). 3. Patients with ‘moderate’ COVID-19 disease severity, as defined by Comprehensive Guidelines for Management of COVID-19 patients, Directorate General of Health Services, MoHFW, GOI; AND having any of the following symptoms and signs prior to randomization: a. Fever, cough, with or without sore throat/throat irritation, body ache/headache, malaise/weakness, diarrhoea or gastrointestinal upset, with or without anorexia/nausea/vomiting, with or without loss of smell and/or taste, shortness of breath/breathlessness and difficulty in breathing b. Respiratory rate of >24 to c. SpO2: 90 – 93% on room air 4. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected within 7 days prior to randomization) 5. Elevated CRP, ESR or Ferritin levels 6. In case of female patients of child-bearing potential, a negative urine pregnancy test prior to beginning the therapy. 7. Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent than the same should be obtained from legally acceptable representative (LAR)
Exclusion criteria
Exclusion criteria: 1. Patients with ‘mild’ or ‘severe’ COVID-19 disease severity, as defined by latest Comprehensive Guidelines for Management of COVID-19 patients, Directorate General of Health Services, MoHFW, GOI at the time of randomization. This includes any one or more of the following a. Peripheral Blood oxygen saturation =94% or b. Respiratory Rate or 2. First positive RT-PCR more than 7 days prior to treatment administration 3. Patients with evidence of other serious infectious, malignant, autoimmune, kidney, hepatic, cardiovascular or other systemic disease and/or laboratory abnormality, which, in the opinion of the investigator, prevent the patient from participating in the study 4. Subjects with Chronic liver disease (Child Pugh class B or C) and chronic renal disease (GFR 5. Renal dysfunction [Serum Creatinine > 2.5 times of ULN or calculated creatinine clearance 3times ULN & AST/ALT > 5times ULN]. 6. Chronic systemic glucocorticoid treatment or any immunosuppressive treatment 7. History of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) 8. Pregnant and Lactating patients. 9. Patients who require IL-6 inhibitors for management of inflammation at the time of study entry. 10. Subject has a psychiatric disease that is not well controlled where controlled is defined as: stable on a regimen for more than one year. 11. Hospital discharge is anticipated in = 24 hours or anticipated transfer to another hospital which is not a study site within 72 hours. 12. Patients that are currently or have participated in such studies participating in other clinical studies with investigational drug, biological agent or device within 1 month or within 5 half-lives (of the drug/biologic) prior to randomization (whichever is longer).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement or shift in WHO 11-point ordinal scale rating. Timepoint: Time-points: Baseline through Day 10, Day 14 and Day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events (serious/Non-serious, Expected/Unexpected, Related/Non-Related)Timepoint: Time frame: 21 days;All-cause mortality Timepoint: Time frame: 28 days ;Changes in Lab. Safety Values for CBC, LFT, KFT, FPGTimepoint: Changes in Lab. Safety Values for CBC, LFT, KFT, FPG;Discharge Rate from hospitalTimepoint: Time frame: 28 Days;Improvement biochemical inflammatory markers such as CRP,Neutrophil-Lymphocyte(N/L) ratio, D-Dimer, Sr. Ferritin, IL-6, TNF-aTimepoint: Time points: Baseline, Day 14, Day 28;Improvement in COVID-19 Symptoms such as Fever, Heart Rate and Oxygen SaturationTimepoint: Time-points: Baseline through Day 10, Day 14 and Day 28;Improvement in lung injury on Chest HRCTTimepoint: Time frame: Baseline, 14, 28 days;Rate of ICU Admission / Mechanical VentilationTimepoint: Time frame: 28 Days;Requirement of auxiliary oxygen therapyTimepoint: Time frame: 28 Days;Time to respiratory viral clearanceTimepoint: Time points: 3, 7, 10, 14 Days;Vital Signs, Physical Examination & other safety evaluation (ECG) analysisTimepoint: Time frame: 28 days | — |
Countries
India
Contacts
Public ContactAmardeep Singh
Insignia Clinical Services Pvt. Ltd.
Outcome results
None listed